EXPLORE!

Drug to Reduce Bone Marrow Suppression due to Chemotherapy Approved

  884 Views

#Hematology  #Oncology  #Pharmacist  #Pulmonary Medicine  #Radiology 

eMediNexus    14 February 2021

Trilaciclib became the first drug in its class to be approved by the U.S. Food and Drug Administration for reducing the incidence of chemotherapy-induced bone marrow suppression in patients being given chemotherapy for extensive-stage small cell lung cancer.

The drug may provide protection to the bone marrow cells against damage from chemotherapy by inhibition of cyclin-dependent kinase 4/6.

Three randomized, double-blind, placebo-controlled trials conducted in patients with extensive-stage small cell lung cancer randomized a total of 245 patients to either trilaciclib or a placebo prior to chemotherapy. Patients given trilaciclib were found to have reduced odds of having severe neutropenia in comparison with patients receiving a placebo. Among the patients who had severe neutropenia, those on trilaciclib treatment had it for a shorter duration on average, compared to patients who received a placebo… (FDA, February 12, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.